A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Tria
(See required screening study ECOG-ACRIN EAY191)
The ovarian cohort of EAY191-N4 is closed to accrual, effective March 3, 2026.
